737Accesses
3Altmetric
Abstract
Nearly every component of hemostasis is altered in sickle cell disease (SCD), yet little evidence exists to guide utilization of venous thromboembolism prophylaxis (VTEP) in this population. This retrospective cohort study included 135 adult patients admitted with a diagnosis of SCD vaso-occlusive crisis to the general medicine service at a tertiary care academic medical center from August 1, 2011 to August 1, 2013. If VTEP was discontinued, the medical record was reviewed for suspicion of VTE, hemorrhage, heparin-induced thrombocytopenia (HIT), or other adverse events. The primary objective was to characterize the safety and effectiveness of VTEP in SCD. The secondary objective was to assess the correlation of VTE with risk factors documented in the general medical population. Most patients (116/135, 85.9%) were prescribed VTEP upon admission, with early discontinuation in 23 patients (19.8%). Reasons for discontinuation included suspicion of VTE (10/116, 8.6%), hemorrhage (5/116, 4.3%), and/or HIT (4/116, 3.4%). Since patients with SCD receiving standard VTEP regimens appear to have similar outcomes compared to medically ill patients in prospective studies, using these regimens appears to be safe when indicated in the opinion of the provider. Once daily injections may be preferred in order to optimize adherence.
This is a preview of subscription content,log in via an institution to check access.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
Buy Now
Price includes VAT (Japan)
Instant access to the full article PDF.
Similar content being viewed by others
References
Centers for Disease Control and Prevention (2011) Sickle Cell Disease (SCD). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta.http://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed 8 Aug 2013
Ataga KI, Key NS (2007) Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology 1:91–96
Naik RP, Streiff MB, Lanzkron S (2013) Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 35:352–358
Stein PD, Beemath A, Meyers FA, Skaf E et al (2006) Deep venous thrombosis and pulmonary embolism in hospitalized patients in sickle cell disease. Am J Med 119(10):897.e7–897.e11
Naik RP, Streiff MB, Haywood C Jr et al (2014) Venous thromboembolism incidence in the cooperative study of sickle cell disease. J Thromb Haemost 12(12):2010–2016
Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV (2012) Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost 10:760–766
Pendleton R, Wheeler M, Rodgers G (2005) Venous thromboembolism prevention in the acutely ill medical patient: a review of the literature and focus on special patient populations. Am J of Hematol 79:229–237
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
Naik RP, Streiff MB, Haywood C, Nelson JA et al (2013) Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 126(5):443–449
Alikhan R, Cohen AT, Combe S, Samama MM et al (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 164(9):963–968
Kakkar AK, Cimminiello C, Goldhaber SZ et al (2011) Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 365:2463–2472
Jeng MR, Feusner J, Skibola C, Vichinsky E (2002) Central venous catheter complications in sickle cell disease. Am J Hematol 69:103–108
Acknowledgements
This project was supported by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Number UL1 TR000062. I would like to acknowledge Petra A. Aldridge, MS for her contributions to statistical analysis.
Author information
Authors and Affiliations
Department of Pharmacy, UF Health Jacksonville Medical Center, Jacksonville, FL, 32209, USA
Denise Kelley
Department of Pharmacy, Ralph H. Johnson VA Medical Center, Charleston, SC, 29425, USA
Lauren Thornton Jones
Presbyterian College of Pharmacy, Clinton, SC, 29325, USA
Jun Wu
Medical Univeristy of South Carolina College of Pharmacy, 280 Calhoun Street QE 205, Charleston, SC, 29425, USA
Nicole Bohm
- Denise Kelley
You can also search for this author inPubMed Google Scholar
- Lauren Thornton Jones
You can also search for this author inPubMed Google Scholar
- Jun Wu
You can also search for this author inPubMed Google Scholar
- Nicole Bohm
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toNicole Bohm.
Ethics declarations
Conflict of interest
The authors have nothing to disclose concerning personal or financial relationships with commercial entities.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Institutional Review Board deemed informed consent not necessary for this study.
Rights and permissions
About this article
Cite this article
Kelley, D., Jones, L.T., Wu, J.et al. Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease.J Thromb Thrombolysis43, 463–468 (2017). https://doi.org/10.1007/s11239-016-1463-z
Published:
Issue Date:
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative